Article
Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy.
Psychiatry and clinical neurosciences - 1 Aug 1997
Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, Ishizaki T, Kubota T
Abstract excerpt
The relationship between the genetic polymorphism of S-mephenytoin 4'-hydroxylation catalyzed by CYP2C19 and the N-demethylation of imipramine was examined in 10 Japanese depressed patients. Five patients, who were poor metabolizers of S-mephenytoin, were determined to be either homozygous for a...
Topics
- Adult
- Antidepressive Agents, Tricyclic
- Aryl Hydrocarbon Hydroxylases
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 Enzyme System
- DNA Mutational Analysis
- Depressive Disorder, Major
- Dose-Response Relationship, Drug
- Exons
- Female
- Genetic Carrier Screening
- Genotype
- Humans
- Imipramine
